Recent Updates
Recently added Catalysts

BNT3211

Phase 1/2

Advanced Solid Tumor | Biologics | Oncology |BioNTech SE|Trials Updated: Nov 20, 2026

BNT3211 development status

Highest phase Phase 1/2
Registered trials 1 across 1 sponsor since Nov 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

CONTROLLED
Total Trials1
Total Enrollment345

FDA Designations

No designations recorded

BNT3211 clinical trials

BNT3211 · 1 trial · 1 indication

Phase 1/2 1
NCT07951359A First-in-human, Dose Escalation, and Expansion Study of BNT3211 for Participants With Advanced Solid TumorsAdvanced Solid Tumor
NOT YET_RECRUITING345 Analytics
PHASE1/PHASE2NOT YET_RECRUITING
A First-in-human, Dose Escalation, and Expansion Study of BNT3211 for Participants With Advanced Solid Tumors
Advanced Solid TumorUnlock trial analytics

Study Endpoints

Primary Endpoints

Part A only - Occurrence of dose-limiting toxicities (DLTs) during the DLT evaluation period
Up to 21 days from the initiation of first dose of BNT3211

DLT period defined as the first 21 days. Per dose level.

Number of participants with treatment emergent adverse events (TEAEs), Grade ≥3 TEAEs, serious adverse events (SAEs), treatment-related TEAEs, treatment-related Grade ≥3 TEAEs, and treatment-related SAEs
From first dose until 35 days after the last dose of BNT3211 (up to 36 months)

Per dose level (Part A) and per arm (Part B).

Number of participants with dose interruptions, reductions, or discontinuations of study treatment due to TEAEs
From the first until the last dose of BNT3211 (up to 36 months)

Per dose level (Part A) and per arm (Part B).

Part B only - Objective response rate
Up to 36 months

Defined as the proportion of participants with confirmed complete response (CR) or partial response (PR) (per the Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v1.1\] based on the investigator's assessment) is observed as best overall response. Per arm.

Secondary Endpoints

PK assessment: Area under the curve (AUC) derived from serum concentrations of BNT3211, total antibody and unconjugated payload
Up to approximately 35 days after the last dose of BNT3211 (up to 36 months)
PK assessment: Maximum concentration (Cmax) derived from serum concentrations of BNT3211, total antibody and unconjugated payload
Up to approximately 35 days after the last dose of BNT3211 (up to 36 months)
PK assessment: Time to reach maximum (peak) serum concentration (Tmax) derived from serum concentrations of BNT3211, total antibody and unconjugated payload
Up to approximately 35 days after the last dose of BNT3211 (up to 36 months)
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Part A (dose escalation) - BNT3211 monotherapyEXPERIMENTALEscalating dose levels of BNT3211.
Part B (dose optimization) - BNT3211 monotherapyEXPERIMENTALIndications as in Part A. Doses will be selected from Part A.

Interventions

NameTypeDescription
BNT3211BIOLOGICALIntravenous infusion
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo

Key Inclusion Criteria: * Are ≥18 years of age (local laws will be followed if the age of consent is older). * Have an Eastern Cooperative Oncology Group performance status of 0 to 1. * Have a life expectancy of ≥3 months in the opinion of the investigator. * Have at least one measurable lesion as ...

Unlock Eligibility Criteria

Competitive Landscape -Other Solid Tumors 10 trials (matched to "Advanced Solid Tumor")

Recent Changes (Last 90 Days)

LOWNov 20, 2026NCT07951359New Trial Detected: Not Yet Recruiting

Frequently asked questions about BNT3211

What is BNT3211 used for?

BNT3211 is an investigational biologic being studied for the treatment of advanced solid tumors. It is in Phase 1/2 clinical development and is not yet available as a marketed therapy. The study enrolls adults 18 years and older with advanced solid tumors.

Who is developing BNT3211?

BNT3211 is being developed by BioNTech SE, which trades on Nasdaq under the ticker BNTX. BioNTech is the sponsor of the first-in-human study evaluating the agent in advanced solid tumors.

What phase is BNT3211 in?

BNT3211 is in Phase 1/2 development. It is investigational and is being evaluated in a first-in-human dose escalation and expansion study. No Phase 3 trial of BNT3211 has been registered.

What clinical trial is BNT3211 in?

BNT3211 is being studied in NCT07951359, a first-in-human, dose escalation, and expansion study for participants with advanced solid tumors. The trial is Phase 1/Phase 2, is not yet recruiting, and plans to enroll 345 participants aged 18 years and older.

Is BNT3211 biomarker-selected?

No. The BNT3211 study enrolls participants with advanced solid tumors without a biomarker-selection requirement, and it accepts all sexes among adults 18 years and older. The trial is controlled but is not randomized and is not double-blind.